Overview

DNAJB1 is altered in 1.00% of all cancers with high grade ovarian serous adenocarcinoma, breast invasive ductal carcinoma, fibrolamellar carcinoma, colon adenocarcinoma, and bladder urothelial carcinoma having the greatest prevalence of alterations [3].

The most common alterations in DNAJB1 are DNAJB1 Amplification (0.40%), DNAJB1-PRKACA Fusion (0.09%), DNAJB1 Loss (0.04%), DNAJB1 E43del (0.01%), and DNAJB1 E62K (0.01%) [3].

Significance of DNAJB1 in Diseases

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.